Novo Nordisk asserts its acquisition of Metsera won't pose antitrust problems as it competes with Pfizer for dominance in the ...

Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.

Pfizer's lawsuits target Metsera, its directors, and Novo Nordisk for breach of contract and antitrust violations, focusing on Novo Nordisk's acquisition proposal. The first lawsuit claims Novo ...

After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the ...

Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for ...

Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Pfizer accused Novo Nordisk of trying to stifle competition in the weight-loss market by attempting to acquire obesity startup Metsera, the second lawsuit in four days as Pfizer tries to retain its ...

Pfizer ( PFE) is set to report its Q3 earnings on Tuesday, November 4, before the market opens. Wall Street expects earnings ...

Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.

The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by ...